
About Indrayani Biotech
Indrayani Biotech is a publicly listed company based in Chennai (India) founded in 1992. Diversified crop nutrition and protection solutions are provided for farmers. The company has 445 employees. Its Indian entity Indrayani Biotech Limited reported revenue of βΉ142 Cr. Indrayani Biotech offers products and services including Bio-Fertilizers, Bio-pest Controllers, and Contract Catering. Its focus areas include Food and Agriculture Tech, Crop Tech, Farm Inputs and Biologicals. Its competitors include IPL Biologicals, Titan Biotech and Univia; 2 of its 3 listed competitors have raised funding.
Company details
Founded in 1992 and based in Chennai, India, operations focus on the agricultural biotechnology sector. Bio fertilizers, bio pesticides, bio fungicides, and bio tonics are offered for field crop protection and nutrition. Neem-based compost is included in the product range. Turnkey projects and consultancy services are also provided to support farming needs.
- Headquarters Chennai, India
- Employees 445
- Stage Public
- SectorsAgriculture
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website indrayani.com
- Legal Name Indrayani Biotech Ltd.
- Market Cap₹73.53 Cr
INDRANIB · BSE
- Share Price₹9.88
+4.88% today
- Revenue₹138 Cr
FY 2025-26 · +5.8% YoY
- EBITDA₹9.63 Cr
Margin 7.0%
- Net Profit₹2.16 Cr
FY 2025-26 · +135.4% YoY
- P/E (TTM)34.5x
P/B 0.6x
- Employee Count445
Associated legal entities of Indrayani Biotech
Indrayani Biotech is associated with 2 registered companies on The Company Check; the primary company is Indrayani Biotech Limited, a listed company. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Indrayani Biotech Limited Listed CIN L40100TN1992PLC129301 | Active | 09 Mar 1992 | Chennai, Tamil Nadu | ₹142 Cr | 445 | 7 | View details |
| Ibl Laksha Hospitals Llp CIN ABA-8136 | Active | 24 Feb 2022 | Chennai, Tamil Nadu | 2 | View details |
Products & Services of Indrayani Biotech
Indrayani Biotech offers a comprehensive portfolio of products and services, including Bio-Fertilizers, Bio-pest Controllers, and Contract Catering.
Microorganism-based fertilizers for enhancing soil and crop growth.
Products using microorganisms to control pests in agriculture.
Services for corporate administrative and hospitality needs.
Board of directors of Indrayani Biotech Limited (Indrayani Biotech)
Indrayani Biotech Limited is the primary company behind Indrayani Biotech. The boards of the 2 registered companies of Indrayani Biotech currently have 7 directors; the longest-serving is Nangavaram Mahadevan Ranganathan, appointed in 2018. 26 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Nangavaram Mahadevan Ranganathan DIN 06377402 | Director | 20 Aug 2018 | 8 yrs 2 mo | Indrayani Biotech Limited |
| Kannimangalam Subramanyan Vaidyanathan DIN 01122393 | Director | 20 Aug 2018 | 8 yrs 2 mo | Indrayani Biotech Limited |
| Swaminathan Govindarajan DIN 02481041 | Whole-time director | 01 Aug 2020 | 6 yrs 3 mo | Indrayani Biotech Limited |
| Muthukrishnan Ramesh DIN 01016291 | Whole-time director | 04 Jan 2021 | 5 yrs 10 mo | Indrayani Biotech Limited |
| Bokara Nagarajan Padmaja Priyadarshini DIN 06416242 | Director | 26 Mar 2021 | 5 yrs 7 mo | Indrayani Biotech Limited |
| Kasiraman Sayee Sundar DIN 01295584 | Designated Partner | 24 Feb 2022 | 4 yrs 8 mo | Ibl Laksha Hospitals Llp, Indrayani Biotech Limited |
| Dhinakaran Rajagopal DIN 09115326 | Designated Partner | 17 Feb 2025 | 1 yr 8 mo | Ibl Laksha Hospitals Llp |
People of Indrayani Biotech
1 people are tracked at Indrayani Biotech (1 in leadership); the tracked headcount is 445.
| Name | Role | Group |
|---|---|---|
| Managing Director | Leadership |
Complete people profiles for Indrayani Biotech
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Indrayani Biotech
Indrayani Biotech is a publicly listed company on the BSE with ticker symbol INDRANIB in India, operating in the Consumer services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date17 May 1994
- Listed onBSE: 526445
- Listed entityIndrayani Biotech Ltd.
- Exchange sectorConsumer services
- ISININE007C01021
- Share price₹8.39 (-1.18% on the day) · 2026-10-14
- Market capitalisation₹38.7 Cr
- Price to earnings14.4
- EPS (diluted, trailing year)₹0.58
- Volume (last session)114,198
Financials of Indrayani Biotech
Exchange-reported figures of Indrayani Biotech Limited, the listed company behind Indrayani Biotech (BSE: INDRANIB).
Financial Highlights
FY 2025-26 Β· ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 138 | 130 | 166 | 163 | 61.57 | 21.09 | 49.90 |
| Revenue growth | +5.8% | -21.7% | +2.0% | +164.6% | +191.9% | -57.7% | - |
| EBITDA | 9.63 | 6.38 | 23.66 | 16.82 | 6.78 | (9.05) | 2.77 |
| EBITDA margin | +7.0% | +4.9% | +14.2% | +10.3% | +11.0% | -42.9% | +5.6% |
| Profit before tax | 0.30 | (5.74) | 10.97 | 12.32 | 4.45 | (11.21) | 0.81 |
| Net profit | 2.16 | (6.10) | 6.36 | 9.24 | 4.45 | (7.10) | 0.81 |
| Net profit margin | +1.6% | -4.7% | +3.8% | +5.7% | +7.2% | -33.7% | +1.6% |
| EPS (βΉ) | 0.48 | (1.34) | 1.40 | 2.55 | 1.30 | (3.28) | 2.22 |
| Balance sheet | |||||||
| Total assets | - | 237 | 189 | 119 | 43.36 | 35.62 | 44.58 |
| Net worth | - | 72.52 | 67.22 | 55.09 | 24.17 | 19.72 | 30.83 |
| Total debt | - | 137 | 113 | 70.19 | 18.80 | 15.54 | 13.74 |
| Cash & bank | - | 0.29 | 0.58 | 3.04 | 1.50 | 0.68 | 1.40 |
| Net working capital | - | 147 | 99.77 | 40.11 | 10.88 | 4.73 | 12.30 |
| Cash flow | |||||||
| Cash from operations | - | (6.74) | (30.35) | 16.19 | 4.11 | 0.26 | 5.96 |
| Cash from investing | - | 24.74 | (16.34) | (47.39) | (0.56) | (0.70) | (3.67) |
| Cash from financing | - | (18.30) | 44.24 | 32.74 | (2.73) | (0.28) | (1.28) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 37.71 | 37.76 | 35.01 | 35.95 | 29.10 | 50.57 | 17.32 | 30.81 |
| Revenue growth (YoY) | +29.6% | -25.3% | +102.1% | +16.7% | -7.7% | +14.0% | - | - |
| Other income | 1.59 | 0.88 | 0.83 | 1.80 | 1.06 | 2.78 | 0.00 | 0.30 |
| EBITDA | 1.47 | 2.21 | 2.78 | 2.45 | 2.18 | (5.74) | 2.92 | 5.10 |
| EBITDA margin | +3.9% | +5.9% | +7.9% | +6.8% | +7.5% | -11.4% | +16.9% | +16.6% |
| Depreciation | 1.10 | 1.13 | 1.01 | 1.30 | 0.86 | (1.72) | 1.46 | 2.79 |
| Interest | 1.37 | 3.08 | 2.47 | 1.89 | 2.17 | 7.07 | 1.03 | 1.42 |
| Profit before tax | 0.59 | (1.12) | 0.13 | 1.06 | 0.21 | (8.31) | 0.43 | 1.19 |
| Tax | 0.05 | (2.08) | 0.03 | 0.15 | 0.05 | 0.21 | 0.08 | (0.02) |
| Net profit | 0.54 | 0.96 | 0.10 | 0.91 | 0.16 | (8.52) | 0.35 | 1.21 |
| EPS (βΉ) | 0.06 | 0.24 | 0.03 | 0.09 | 0.03 | (1.88) | 0.05 | 0.13 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 21.90 | 37.77 | 62.32 | 74.48 | 57.99 | 21.01 | 49.90 |
| Revenue growth | -42.0% | -39.4% | -16.3% | +28.4% | +176.0% | -57.9% | - |
| EBITDA | 1.58 | 5.56 | 5.80 | 8.23 | 6.25 | (8.77) | 2.77 |
| EBITDA margin | +7.2% | +14.7% | +9.3% | +11.1% | +10.8% | -41.7% | +5.6% |
| Profit before tax | 1.20 | 0.66 | 3.01 | 5.09 | 4.24 | (10.88) | 0.81 |
| Net profit | 0.70 | 1.46 | 1.46 | 5.57 | 4.24 | (6.77) | 0.81 |
| Net profit margin | +3.2% | +3.9% | +2.3% | +7.5% | +7.3% | -32.2% | +1.6% |
| EPS (βΉ) | 0.15 | 0.32 | 0.32 | 1.48 | 1.23 | (3.18) | 2.22 |
| Balance sheet | |||||||
| Total assets | - | 117 | 118 | 93.86 | 40.91 | 35.38 | 44.58 |
| Net worth | - | 55.34 | 54.52 | 51.15 | 24.18 | 19.95 | 30.83 |
| Total debt | - | 61.66 | 63.46 | 42.71 | 16.73 | 15.43 | 13.74 |
| Cash & bank | - | 0.06 | 0.26 | 0.62 | 1.45 | 0.63 | 1.40 |
| Net working capital | - | 67.16 | 64.49 | 42.91 | 9.49 | 4.58 | 12.30 |
| Cash flow | |||||||
| Cash from operations | - | 17.35 | 26.09 | 8.33 | 3.47 | 0.52 | 5.96 |
| Cash from investing | - | (1.34) | (7.26) | (14.09) | 0.59 | (0.56) | (3.67) |
| Cash from financing | - | (16.22) | (19.19) | 4.93 | (3.23) | (0.73) | (1.28) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4.15 | 4.08 | 5.20 | 5.93 | 6.69 | 9.28 | 8.19 | 9.51 |
| Revenue growth (YoY) | -38.0% | -56.0% | -36.5% | -37.6% | -38.0% | -41.3% | - | - |
| Other income | 0.19 | 0.82 | 0.68 | 1.82 | 0.89 | 0.93 | 0.66 | 0.89 |
| Total expenses | 3.26 | 3.88 | 4.54 | 5.97 | 5.94 | 7.56 | 6.86 | 8.07 |
| EBITDA | 0.89 | 0.20 | 0.66 | (0.04) | 0.75 | 1.72 | 1.33 | 1.44 |
| EBITDA margin | +21.4% | +4.9% | +12.7% | -0.7% | +11.2% | +18.5% | +16.2% | +15.1% |
| Depreciation | 0.12 | 0.18 | 0.14 | 0.17 | 0.15 | 0.06 | 0.32 | 0.32 |
| Interest | 0.76 | 0.54 | 1.09 | 0.99 | 1.32 | 2.39 | 1.52 | 1.89 |
| Profit before tax | 0.20 | 0.30 | 0.11 | 0.62 | 0.17 | 0.20 | 0.15 | 0.12 |
| Tax | 0.05 | 0.28 | 0.03 | 0.16 | 0.04 | (0.91) | 0.04 | 0.03 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 37.71 | 37.76 | 35.01 | 35.95 | 29.10 | 50.57 | 17.32 | 30.81 |
| Revenue growth (YoY) | +29.6% | -25.3% | +102.1% | +16.7% | -7.7% | +14.0% | - | - |
| Other income | 1.59 | 0.88 | 0.83 | 1.80 | 1.06 | 2.78 | 0.00 | 0.30 |
| EBITDA | 1.47 | 2.21 | 2.78 | 2.45 | 2.18 | (5.74) | 2.92 | 5.10 |
| EBITDA margin | +3.9% | +5.9% | +7.9% | +6.8% | +7.5% | -11.4% | +16.9% | +16.6% |
| Depreciation | 1.10 | 1.13 | 1.01 | 1.30 | 0.86 | (1.72) | 1.46 | 2.79 |
| Interest | 1.37 | 3.08 | 2.47 | 1.89 | 2.17 | 7.07 | 1.03 | 1.42 |
| Profit before tax | 0.59 | (1.12) | 0.13 | 1.06 | 0.21 | (8.31) | 0.43 | 1.19 |
| Tax | 0.05 | (2.08) | 0.03 | 0.15 | 0.05 | 0.21 | 0.08 | (0.02) |
| Net profit | 0.54 | 0.96 | 0.10 | 0.91 | 0.16 | (8.52) | 0.35 | 1.21 |
| EPS (βΉ) | 0.06 | 0.24 | 0.03 | 0.09 | 0.03 | (1.88) | 0.05 | 0.13 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 138 | 130 | 166 | 163 | 61.57 | 21.09 | 49.90 |
| Revenue growth | +5.8% | -21.7% | +2.0% | +164.6% | +191.9% | -57.7% | - |
| Other income | 4.57 | 3.13 | 1.21 | 4.49 | 0.22 | 0.27 | 0.20 |
| Total expenses | 128 | 124 | 143 | 146 | 54.79 | 30.14 | 47.13 |
| Employee cost | 0.00 | 19.69 | 23.07 | 23.01 | 9.58 | 5.39 | 10.81 |
| EBITDA | 9.63 | 6.38 | 23.66 | 16.82 | 6.78 | (9.05) | 2.77 |
| EBITDA margin | +7.0% | +4.9% | +14.2% | +10.3% | +11.0% | -42.9% | +5.6% |
| Depreciation | 4.30 | 3.37 | 3.80 | 3.35 | 0.66 | 0.46 | 1.01 |
| Interest | 9.60 | 11.88 | 10.10 | 5.64 | 1.89 | 1.97 | 1.15 |
| Profit before tax | 0.30 | (5.74) | 10.97 | 12.32 | 4.45 | (11.21) | 0.81 |
| Tax | (1.86) | 0.36 | 0.55 | 0.37 | 0.00 | 0.00 | 0.00 |
| Net profit | 2.16 | (6.10) | 6.36 | 9.24 | 4.45 | (7.10) | 0.81 |
| Net profit margin | +1.6% | -4.7% | +3.8% | +5.7% | +7.2% | -33.7% | +1.6% |
| EPS (βΉ) | 0.48 | (1.34) | 1.40 | 2.55 | 1.30 | (3.28) | 2.22 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | - | 45.54 | 45.54 | 43.48 | 34.23 | 34.23 | 3.64 |
| Reserves & surplus | - | 23.49 | 17.56 | 10.07 | (10.06) | (14.51) | (3.39) |
| Shareholders' funds (net worth) | - | 72.52 | 67.22 | 55.09 | 24.17 | 19.72 | 30.83 |
| Minority interest | - | 27.41 | 9.05 | (6.73) | 0.41 | 0.36 | 0.00 |
| Secured loans | - | 135 | 108 | 62.75 | 17.89 | 15.54 | 13.05 |
| Unsecured loans | - | 1.64 | 4.86 | 7.44 | 0.91 | 0.00 | 0.69 |
| Total debt | - | 137 | 113 | 70.19 | 18.80 | 15.54 | 13.74 |
| Total liabilities | - | 237 | 189 | 119 | 43.36 | 35.62 | 44.58 |
| Assets | |||||||
| Gross block | - | 102 | 102 | 88.86 | 58.19 | 16.85 | 18.38 |
| Net block | - | 57.68 | 62.42 | 57.48 | 16.51 | 15.38 | 17.37 |
| Capital work in progress | - | 25.67 | 20.30 | 13.74 | 13.27 | 13.72 | 13.59 |
| Investments | - | 0.25 | 0.22 | 0.22 | 0.00 | 0.01 | 0.01 |
| Inventories | - | 41.34 | 42.35 | 12.21 | 1.53 | 1.09 | 5.07 |
| Sundry debtors | - | 58.69 | 39.53 | 29.97 | 14.10 | 4.77 | 7.04 |
| Cash & bank balances | - | 0.29 | 0.58 | 3.04 | 1.50 | 0.68 | 1.40 |
| Loans & advances | - | 77.62 | 62.52 | 32.30 | 1.78 | 2.62 | 5.68 |
| Total current assets | - | 178 | 145 | 77.52 | 18.91 | 9.16 | 19.19 |
| Total current liabilities | - | 30.82 | 45.21 | 37.41 | 8.03 | 4.43 | 6.89 |
| Net working capital | - | 147 | 99.77 | 40.11 | 10.88 | 4.73 | 12.30 |
| Total assets | - | 237 | 189 | 119 | 43.36 | 35.62 | 44.58 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | - | 0.58 | 3.04 | 1.50 | 0.68 | 1.40 | 0.39 |
| Net cash from operating activities | - | (6.74) | (30.35) | 16.19 | 4.11 | 0.26 | 5.96 |
| Net cash from investing activities | - | 24.74 | (16.34) | (47.39) | (0.56) | (0.70) | (3.67) |
| Net cash from financing activities | - | (18.30) | 44.24 | 32.74 | (2.73) | (0.28) | (1.28) |
| Net change in cash | - | (0.29) | (2.45) | 1.53 | 0.82 | (0.72) | 1.01 |
| Closing cash | - | 0.29 | 0.58 | 3.04 | 1.50 | 0.68 | 1.40 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +5.8% | -21.7% | +2.0% | +164.6% | +191.9% | -57.7% | - |
| EBITDA growth | +50.9% | -73.0% | +40.7% | +148.1% | +174.9% | -426.7% | - |
| PBT growth | +9998.0% | - | -11.0% | +176.9% | +9998.0% | - | +9997.0% |
| Net income growth | +135.4% | -195.9% | -31.2% | +107.6% | +162.7% | -976.5% | - |
| Revenue CAGR (3Y) | -5.4% | +28.4% | +99.0% | +48.4% | - | - | - |
| EBITDA CAGR (3Y) | -17.0% | -2.0% | - | +82.4% | - | - | - |
| Profitability & leverage | |||||||
| Net income margin | +1.6% | -4.7% | +6.3% | +7.3% | +7.2% | -53.2% | +1.6% |
| Return on capital employed | - | +3.2% | +13.8% | +20.0% | +14.3% | 0.0% | +4.1% |
| Return on net worth | - | -8.8% | +18.2% | +29.3% | +16.5% | 0.0% | +2.4% |
| Debt / equity | - | 1.79 | 1.49 | 1.12 | 0.78 | 0.58 | 0.45 |
| Long-term debt / equity | - | 0.97 | 0.87 | 0.54 | 0.35 | 0.30 | 0.23 |
| Interest cover | 180.11 | 394.68 | 50.86 | 41.87 | 30.88 | -20.72 | 65.34 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 1.28 | 1.75 | 2.22 | 1.64 | 1.20 | 2.71 |
| Inventory turnover | - | 3.11 | 6.09 | 23.72 | 47.00 | 6.85 | 9.84 |
| Debtors turnover | - | 2.65 | 4.78 | 7.39 | 6.53 | 3.57 | 7.09 |
| EPS (βΉ) | 0.48 | (1.34) | 1.40 | 2.55 | 1.30 | (3.28) | 2.22 |
| Dividend per share (βΉ) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (βΉ) | 0.00 | 15.16 | 13.86 | 12.94 | 7.06 | 5.76 | 0.70 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4.15 | 4.08 | 5.20 | 5.93 | 6.69 | 9.28 | 8.19 | 9.51 |
| Revenue growth (YoY) | -38.0% | -56.0% | -36.5% | -37.6% | -38.0% | -41.3% | - | - |
| Other income | 0.19 | 0.82 | 0.68 | 1.82 | 0.89 | 0.93 | 0.66 | 0.89 |
| Total expenses | 3.26 | 3.88 | 4.54 | 5.97 | 5.94 | 7.56 | 6.86 | 8.07 |
| EBITDA | 0.89 | 0.20 | 0.66 | (0.04) | 0.75 | 1.72 | 1.33 | 1.44 |
| EBITDA margin | +21.4% | +4.9% | +12.7% | -0.7% | +11.2% | +18.5% | +16.2% | +15.1% |
| Depreciation | 0.12 | 0.18 | 0.14 | 0.17 | 0.15 | 0.06 | 0.32 | 0.32 |
| Interest | 0.76 | 0.54 | 1.09 | 0.99 | 1.32 | 2.39 | 1.52 | 1.89 |
| Profit before tax | 0.20 | 0.30 | 0.11 | 0.62 | 0.17 | 0.20 | 0.15 | 0.12 |
| Tax | 0.05 | 0.28 | 0.03 | 0.16 | 0.04 | (0.91) | 0.04 | 0.03 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 21.90 | 37.77 | 62.32 | 74.48 | 57.99 | 21.01 | 49.90 |
| Revenue growth | -42.0% | -39.4% | -16.3% | +28.4% | +176.0% | -57.9% | - |
| Other income | 4.21 | 3.52 | 3.62 | 0.64 | 0.22 | 0.26 | 0.20 |
| Total expenses | 20.32 | 32.21 | 56.52 | 66.25 | 51.74 | 29.78 | 47.13 |
| Employee cost | 0.00 | 12.86 | 15.23 | 17.10 | 8.48 | 5.22 | 10.81 |
| EBITDA | 1.58 | 5.56 | 5.80 | 8.23 | 6.25 | (8.77) | 2.77 |
| EBITDA margin | +7.2% | +14.7% | +9.3% | +11.1% | +10.8% | -41.7% | +5.6% |
| Depreciation | 0.64 | 1.02 | 1.45 | 0.93 | 0.34 | 0.40 | 1.01 |
| Interest | 3.95 | 7.40 | 4.96 | 2.85 | 1.89 | 1.97 | 1.15 |
| Profit before tax | 1.20 | 0.66 | 3.01 | 5.09 | 4.24 | (10.88) | 0.81 |
| Tax | 0.50 | (0.80) | 1.55 | 0.02 | 0.00 | 0.00 | 0.00 |
| Net profit | 0.70 | 1.46 | 1.46 | 5.57 | 4.24 | (6.77) | 0.81 |
| Net profit margin | +3.2% | +3.9% | +2.3% | +7.5% | +7.3% | -32.2% | +1.6% |
| EPS (βΉ) | 0.15 | 0.32 | 0.32 | 1.48 | 1.23 | (3.18) | 2.22 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | - | 45.54 | 45.54 | 43.48 | 34.23 | 34.23 | 3.64 |
| Reserves & surplus | - | 6.31 | 4.86 | 6.13 | (10.05) | (14.28) | (3.39) |
| Shareholders' funds (net worth) | - | 55.34 | 54.52 | 51.15 | 24.18 | 19.95 | 30.83 |
| Secured loans | - | 61.66 | 58.60 | 35.27 | 16.73 | 15.43 | 13.05 |
| Unsecured loans | - | 0.00 | 4.86 | 7.44 | 0.00 | 0.00 | 0.69 |
| Total debt | - | 61.66 | 63.46 | 42.71 | 16.73 | 15.43 | 13.74 |
| Total liabilities | - | 117 | 118 | 93.86 | 40.91 | 35.38 | 44.58 |
| Assets | |||||||
| Gross block | - | 20.53 | 25.80 | 26.50 | 17.09 | 16.53 | 18.38 |
| Net block | - | 16.66 | 21.66 | 23.81 | 15.33 | 15.11 | 17.37 |
| Capital work in progress | - | 18.09 | 18.03 | 12.72 | 13.22 | 13.72 | 13.59 |
| Investments | - | 9.61 | 9.56 | 7.99 | 0.19 | 0.19 | 0.01 |
| Inventories | - | 1.69 | 1.92 | 1.86 | 1.37 | 1.08 | 5.07 |
| Sundry debtors | - | 16.46 | 17.60 | 16.23 | 12.88 | 4.77 | 7.04 |
| Cash & bank balances | - | 0.06 | 0.26 | 0.62 | 1.45 | 0.63 | 1.40 |
| Loans & advances | - | 62.42 | 51.72 | 30.62 | 2.31 | 2.56 | 5.68 |
| Total current assets | - | 80.63 | 71.50 | 49.33 | 18.01 | 9.04 | 19.19 |
| Total current liabilities | - | 13.47 | 7.01 | 6.42 | 8.52 | 4.46 | 6.89 |
| Net working capital | - | 67.16 | 64.49 | 42.91 | 9.49 | 4.58 | 12.30 |
| Total assets | - | 117 | 118 | 93.86 | 40.91 | 35.38 | 44.58 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | - | 0.26 | 0.62 | 1.45 | 0.63 | 1.40 | 0.39 |
| Net cash from operating activities | - | 17.35 | 26.09 | 8.33 | 3.47 | 0.52 | 5.96 |
| Net cash from investing activities | - | (1.34) | (7.26) | (14.09) | 0.59 | (0.56) | (3.67) |
| Net cash from financing activities | - | (16.22) | (19.19) | 4.93 | (3.23) | (0.73) | (1.28) |
| Net change in cash | - | (0.20) | (0.36) | (0.83) | 0.82 | (0.78) | 1.01 |
| Closing cash | - | 0.06 | 0.26 | 0.62 | 1.45 | 0.63 | 1.40 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -42.0% | -39.4% | -16.3% | +28.4% | +176.0% | -57.9% | - |
| EBITDA growth | -71.6% | -4.1% | -29.5% | +31.7% | +171.3% | -416.6% | - |
| PBT growth | +81.8% | -78.1% | -40.9% | +20.1% | +9998.0% | - | +9998.0% |
| Net income growth | -52.1% | 0.0% | -73.8% | +31.4% | +162.6% | -935.8% | - |
| Revenue CAGR (3Y) | -33.5% | -13.3% | +43.7% | +14.3% | - | - | - |
| EBITDA CAGR (3Y) | -42.3% | -3.8% | - | +43.8% | - | +307.1% | - |
| Profitability & leverage | |||||||
| Net income margin | +3.2% | +3.9% | +2.3% | +6.8% | +7.3% | -51.8% | +1.6% |
| Return on capital employed | - | +6.7% | +7.2% | +10.6% | +14.2% | 0.0% | +8.2% |
| Return on net worth | - | +2.5% | +2.8% | +12.5% | +15.6% | 0.0% | +4.8% |
| Debt / equity | - | 1.14 | 1.00 | 0.79 | 0.73 | 0.57 | 0.48 |
| Long-term debt / equity | - | 0.30 | 0.33 | 0.30 | 0.34 | 0.30 | 0.25 |
| Interest cover | 420.21 | 163.00 | 114.02 | 39.04 | 31.98 | -21.48 | 65.34 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 1.63 | 2.38 | 3.42 | 3.45 | 1.20 | 5.43 |
| Inventory turnover | - | 20.93 | 32.97 | 46.12 | 47.34 | 6.83 | 19.68 |
| Debtors turnover | - | 2.22 | 3.68 | 5.12 | 6.57 | 3.56 | 14.18 |
| EPS (βΉ) | 0.15 | 0.32 | 0.32 | 1.48 | 1.23 | (3.18) | 2.22 |
| Dividend per share (βΉ) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (βΉ) | 0.00 | 11.39 | 11.07 | 11.79 | 7.06 | 5.83 | 0.70 |
Competitors of Indrayani Biotech
Indrayani Biotech has 3 listed competitors in our database, 2 of them funded. They include IPL Biologicals, Titan Biotech and Univia.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| iplbiologicals.com | 1994 | Gurugram, India | $4.66M | 901 | Plant nutrition and protection products are manufactured and supplied. | |
| titanbiotechltd.com | 1992 | Delhi, India | 406 | Biological products are manufactured and exported for various industries. | ||
| univia.in | 2020 | Ahmedabad, India | $237,838 | 52 | Agri-input retailers are connected to farmers via a phygital network. |
Detailed competitors of Indrayani Biotech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Indrayani Biotech
The website of Indrayani Biotech (indrayani.com) receives about 1.1K visits a month.
- Monthly visits1.1K
▲ 9.7% vs previous month
Websites whose visitors overlap most with Indrayani Biotech. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| google.com | 100% | 85.8B | #1 | View details | |
indiabiotech.in | indiabiotech.in | 68% | β |
Top companies in Crop Tech & Equipment
3 companies that operate in the same segment as Indrayani Biotech (Crop Tech & Equipment) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Provider of climate-smart deeptech solutions for renewable energy and sustainable agriculture | 2010 | Pune, Maharashtra, India | USD 76.38 M | USD 56.11 M | 702 | |
Manufacturer and distributor of irrigation equipment | 1963 | Jalgaon, Maharashtra, India | USD 679.04 M | 2,764 | ||
AgroStar is engaged in providing agricultural products and solutions. | 2013 | Pune, Maharashtra, India | USD 208.82 M | USD 104.54 M | 1,456 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Indrayani Biotech
Complete news archive for Indrayani Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Indrayani Biotech
Indrayani Biotech was founded in 1992.
Indrayani Biotech is headquartered in Chennai, India. It is registered at Chennai, Tamil Nadu, India.
Indrayani Biotech has 445 employees.
The primary company behind Indrayani Biotech, Indrayani Biotech Limited, reported revenue of βΉ142 Cr for FY 2026, up 6% year on year.
Founded in 1992 and based in Chennai, India, operations focus on the agricultural biotechnology sector. Bio fertilizers, bio pesticides, bio fungicides, and bio tonics are offered for field crop protection and nutrition. Neem-based compost is included in the product range. Turnkey projects and consultancy services are also provided to support farming needs.
Indrayani Biotech's top competitors include Titan Biotech, IPL Biologicals and Univia.
Indrayani Biotech offers Bio-Fertilizers, Bio-pest Controllers, and Contract Catering.
Yes, Indrayani Biotech is publicly traded on BSE under the ticker symbol INDRANIB.
Indrayani Biotech is associated with 2 legal entities: Indrayani Biotech Limited, Ibl Laksha Hospitals Llp.
The legal entities of Indrayani Biotech currently have 8 directors, including Dhinakaran Rajagopal, Kasiraman Sayee Sundar, Nangavaram Mahadevan Ranganathan and others.
